In those with NSCLC harboring EGFR exon20ins post platinum-based therapy (N = 114), the ORR was 40% (95% CI: 29–51%) with a median DOR of 11.1 months (95% CI: 6.9-NR) [Sabari WCLC 2021]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.